Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pannexin1-dependent and -independent protection by novel peptidomimetics against cardiac ischemia/reperfusion injury.

Scientific reports·2026

Same author

Reaching Increased Hydrogel Stability <i>In Vivo</i> through β-Hairpin Peptide-Based Hydrogels.

Biomacromolecules·2026

Same author

Dual-target opioid/neurotensin ligands drive potent and safer analgesia in vivo.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Same author

Nano-G<sub>s</sub> Protein Peptidomimetics: Rational Design of Gα C-Terminus-Derived Peptides Mimicking Key Components of G<sub>s</sub>-β<sub>2</sub>AR Interactions.

Angewandte Chemie (International ed. in English)·2026

Same author

Trifluoromethylthio and Trifluoromethyl Functionalization of Endomorphin-1 Enhances its Hydrophobicity and Plasma Stability while Preserving its Affinity for the μ-Opioid Receptor.

The Journal of organic chemistry·2026

Same author

Recruitment of Mre11 to recombination sites during meiosis.

Nature communications·2026

Search research articles

Related Experiment Video

Updated: Oct 9, 2025

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

Downsizing antibodies: Towards complementarity-determining region (CDR)-based peptide mimetics.

Kevin Van Holsbeeck¹, José C Martins², Steven Ballet³

¹Research Group of Organic Chemistry, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium; NMR and Structure Analysis Unit, Ghent University, Krijgslaan 281 S4, 9000 Ghent, Belgium.

Bioorganic Chemistry

|December 23, 2021

Summary

Therapeutic antibody fragments and peptides offer improved cellular access and lower costs compared to traditional monoclonal antibodies. Rational design strategies are key to developing effective CDR-based peptide mimetics.

Keywords:

Antibody Complementarity-determining regions Nanobody Paratope Peptidomimetics

More Related Videos

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library

Published on: January 14, 2020

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

Related Experiment Videos

Last Updated: Oct 9, 2025

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library

Published on: January 14, 2020

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

Area of Science:

Biotechnology
Immunology
Drug Development

Background:

Monoclonal antibodies are effective therapeutics but face limitations like high costs and poor cellular penetration due to their large size (approx. 150 kDa).
Downsized antibody fragments (15-50 kDa) and peptide mimetics (1-3 kDa) derived from complementarity-determining regions (CDRs) have been developed to overcome these limitations.

Purpose of the Study:

To review the development of peptide mimetics derived from antibody and nanobody paratopes.
To focus on the design strategies employed for creating these smaller, functional antibody-derived molecules.
To highlight the challenges encountered in developing CDR-based peptide mimetics.

Main Methods:

Review of literature on antibody fragment and peptide mimetic development.
Analysis of rational structure-based and computational design approaches.
Focus on strategies for mimicking antibody paratopes and CDR loops.

Main Results:

While direct translation of CDR loops into peptides has had limited success, rational design approaches show promise.
Development of smaller antibody fragments and CDR-derived peptides offers potential for improved therapeutic properties.
Various design strategies are being explored to create functional peptide mimetics.

Conclusions:

Peptide mimetics derived from antibody paratopes represent a promising area for therapeutic development.
Structure-based and computational design are crucial for overcoming challenges in creating functional CDR-based peptides.
Further research into design strategies is needed to fully realize the potential of these antibody-derived therapeutics.